CLBS12

Study Information

A Phase 2 study is underway in Japan evaluating an autologous CD34 cell therapy (CLBS12) for the treatment of no-option critical limb ischemia (CLI). For more information on this study, please visit www2.tri-kobe.org/clbs12.
Status: Active - Enrolling